Immune checkpoint inhibitors: new strategies to checkmate cancer
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Summary: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or programmed cell death protein 1 (PD-1) receptors have demonstrated remarkable efficacy in subsets of patients with malignant disease. This emerging treatment modality holds great promise for future cancer treatment and has engaged pharmaceutical research interests in tumour immunology. While ICIs can induce rapid and durable responses in some patients, identifying predictive factors for effective clinical responses has proved challenging. This review summarizes the mechanisms of action of ICIs and outlines important preclinical work that contributed to their development. We explore clinical data that has led to disease-specific drug licensing, and highlight key clinical trials that have revealed ICI efficacy across a range of malignancies. We describe how ICIs have been used as part of combination therapies, and explore their future prospects in this area. We conclude by discussing the incorporation of these new immunotherapeutics into precision approaches to cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 16×
“In an open-label, randomized, Phase III study involving patients with ipilimumab-refractory melanoma, nivolumab was associated with a higher ORR than chemotherapy (32 versus 11”
BackgroundInfluentialNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · cited 1×
“Pembrolizumab treatment gave a clinically significant ORR, and durable responses were evident in some patients [132], while nivolumab improved overall survival compared to standard singleagent therapy (methotrexate, docetaxel or cetuximab) [133].”
BackgroundDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 2×
“The phase II trial using atezolizumab improved objective response rates compared with a historical control [124].”
MethodGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Genomic and transcriptomic analysis of pre-treatment melanoma has identified a transcriptional signature associated with innate resistance to anti-PD1 therapy, and demonstrated that mutations in the DNA repair gene BRCA2 are enriched in patients that do respond [161].”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“Interestingly, one study has identified mutations in melanoma cells in patients whose disease progressed after initially responding to PD-1 blockade [162], and at least one trial is underway that aims to understand the selection pressures and evolutionary changes that ICIs impose on tumour cells [163].”
BackgroundMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Cited by
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00517-1 · Cited by 697
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1247 · Cited by 275
Self-citation
Metadata
- Authors
- Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-27
- Volume
- 191
- Issue
- 2
- Pages
- 133-148
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2769633802
- Cited by
- 70
- References
- 48
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune checkpoint inhibitors: new strategies to checkmate cancer. https://app.cochat.ai/papers/10.1111/cei.13081
- The paper
- Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018). Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology. https://doi.org/10.1111/cei.13081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.